CA2092420A1 - Vaccin anti-Bortedella Pertussis - Google Patents

Vaccin anti-Bortedella Pertussis

Info

Publication number
CA2092420A1
CA2092420A1 CA2092420A CA2092420A CA2092420A1 CA 2092420 A1 CA2092420 A1 CA 2092420A1 CA 2092420 A CA2092420 A CA 2092420A CA 2092420 A CA2092420 A CA 2092420A CA 2092420 A1 CA2092420 A1 CA 2092420A1
Authority
CA
Canada
Prior art keywords
omps
bordetella pertussis
combatting
formulation
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2092420A
Other languages
English (en)
Other versions
CA2092420C (fr
Inventor
Hendrik-Jan Hamstra
Jan Teunis Poolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of Netherlands
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2092420A1 publication Critical patent/CA2092420A1/fr
Application granted granted Critical
Publication of CA2092420C publication Critical patent/CA2092420C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des vaccins adaptés à la lutte contre Bordetella Pertussis, l'organisme provoquant la coqueluche. Les vaccins comprennent notamment, à titre de constituant actif, une ou plusieurs protéines membranaires extérieures (OMP) dérivées de Bordetella pertussis ou de micro-organismes ayant subi une manipulation génétique et produisant lesdites OMP. Les OMP ayant une masse moléculaire d'environ 32 kDa et 92 kDa (soit séparément soit une combinaison des deux) sont de préférence utilisés comme constituants actifs. Selon un mode de réalisation de l'invention, les OMP en question sont présentes dans une formulation de vésicule membranaire extérieure (OMV) ou dans une formulation de vésicule artificielle analogue à une formulation de protéines-détergent.
CA002092420A 1990-09-25 1991-09-25 Vaccin anti-bortedella pertussis Expired - Fee Related CA2092420C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL9002092A NL9002092A (nl) 1990-09-25 1990-09-25 Vaccin, geschikt voor de bestrijding van bordetella pertussis.
NL9002092 1990-09-25
PCT/NL1991/000185 WO1992005194A1 (fr) 1990-09-25 1991-09-25 Vaccin adapte a la lutte contre bordetella pertussis

Publications (2)

Publication Number Publication Date
CA2092420A1 true CA2092420A1 (fr) 1992-03-26
CA2092420C CA2092420C (fr) 1999-11-23

Family

ID=19857724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092420A Expired - Fee Related CA2092420C (fr) 1990-09-25 1991-09-25 Vaccin anti-bortedella pertussis

Country Status (8)

Country Link
EP (1) EP0550683B1 (fr)
AT (1) ATE121423T1 (fr)
CA (1) CA2092420C (fr)
DE (1) DE69109126T2 (fr)
DK (1) DK0550683T3 (fr)
ES (1) ES2073180T3 (fr)
NL (1) NL9002092A (fr)
WO (1) WO1992005194A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156958A (en) * 1990-09-21 1992-10-20 American Cyanamid Company Gene encoding a 30 kilodalton outer membrane protein of bordetella pertussis and method of recombinant production of said protein
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
BR9609882A (pt) * 1995-08-04 1999-07-27 Univ Guelph Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
FR2805163A1 (fr) * 2000-02-21 2001-08-24 Pf Medicament Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
CN118853525B (zh) * 2024-09-26 2025-01-07 上海羽冠生物技术有限公司 经修饰的百日咳鲍特菌菌株

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504656A (ja) * 1989-03-31 1992-08-20 ワシントン ユニバーシティー ボルデテラワクチン
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)

Also Published As

Publication number Publication date
DE69109126T2 (de) 1995-09-21
DK0550683T3 (da) 1995-09-04
NL9002092A (nl) 1992-04-16
ES2073180T3 (es) 1995-08-01
ATE121423T1 (de) 1995-05-15
DE69109126D1 (de) 1995-05-24
EP0550683B1 (fr) 1995-04-19
WO1992005194A1 (fr) 1992-04-02
EP0550683A1 (fr) 1993-07-14
CA2092420C (fr) 1999-11-23

Similar Documents

Publication Publication Date Title
ITFI920058A1 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini.
DE69022106D1 (de) Pertussistoxin-Mutanten, dieselbe produzierende Bordetella-Stämme und ihre Verwendung als Vakzin gegen Pertussis.
AU4533589A (en) Skin test and test kit for aids
NL300401I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
EP1712628A3 (fr) Composés et procédés pour l'immunothérapie et le diagnostic de la tuberculose
CA2215203A1 (fr) Vaccins contre la peste
CA2231603A1 (fr) Interleukine-15 du poulet et ses utilisations
CA2220063A1 (fr) Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants
FI972054A0 (fi) Immunogeenisiä koostumuksia
WO1997005899A3 (fr) Nouveaux vaccins et nouvelles compositions pharmaceutiques utilisant des vesicules de membrane de micro-organismes et leurs procedes d'elaboration
DK0550683T3 (da) Vaccine egnet til bekæmpelse af Borderella pertussis
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
CA2361377A1 (fr) Nouveau systeme d'administration par les muqueuses
NO951750D0 (no) Renset "nontypable" Haemophilus influenzae P5 protein som en vaksine for "nontypable" Haemophilus influenzae stamme
AU5625796A (en) Protective epitopes of adenyl cyclase-haemolysin(AC-Hly), their application to the treatment or to the prevention of bordetella infections
CA2004206A1 (fr) Methodes de preparation de l'anatoxine coquelucheuse
CA2133108A1 (fr) Vaccin a base de toxoide contre pasteurella haemolytica type a-1
CA2015828A1 (fr) Vaccin contre le corona virus canin
CA2087003A1 (fr) Vaccin anti-vrs humain
IT8722791A0 (it) Attenuato cosi' ottenuto. procedimento per la preparazione di un ceppo mutante migliorato di bordetella bronchiseptica utile per un vaccino attenuato vivo per la protezione da infezioni di b.bronchiseptica e vaccino ar vivo

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed